Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic efficacy

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib is an emerging cancer therapeutic that just recently gained Food and Drug Administration approval for treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor (Her)2-negative breast cancer in combination w...

Descripción completa

Detalles Bibliográficos
Autores principales: Arndt, Claudia, Tunger, Antje, Wehner, Rebekka, Rothe, Rebecca, Kourtellari, Eleni, Luttosch, Stephanie, Hannemann, Katharina, Koristka, Stefanie, Loureiro, Liliana R., Feldmann, Anja, Tonn, Torsten, Link, Theresa, Kuhlmann, Jan Dominik, Wimberger, Pauline, Bachmann, Michael Philipp, Schmitz, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935825/
https://www.ncbi.nlm.nih.gov/pubmed/36817127
http://dx.doi.org/10.3389/fphar.2023.970457

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935825/
https://www.ncbi.nlm.nih.gov/pubmed/36817127
http://dx.doi.org/10.3389/fphar.2023.970457

Ejemplares similares